Literature DB >> 25500874

FXR and liver carcinogenesis.

Xiong-fei Huang1, Wei-yu Zhao2, Wen-dong Huang2.   

Abstract

Farnesoid X receptor (FXR) is a member of the nuclear receptor family and a ligand-modulated transcription factor. In the liver, FXR has been considered a multi-functional cell protector and a tumor suppressor. FXR can suppress liver carcinogenesis via different mechanisms: 1) FXR maintains the normal liver metabolism of bile acids, glucose and lipids; 2) FXR promotes liver regeneration and repair after injury; 3) FXR protects liver cells from death and enhances cell survival; 4) FXR suppresses hepatic inflammation, thereby preventing inflammatory damage; and 5) FXR can directly increase the expression of some tumor-suppressor genes and repress the transcription of several oncogenes. However, inflammation and epigenetic silencing are known to decrease FXR expression during tumorigenesis. The reactivation of FXR function in the liver may be a potential therapeutic approach for patients with liver cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25500874      PMCID: PMC4571316          DOI: 10.1038/aps.2014.117

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  92 in total

1.  SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.

Authors:  Juan L García-Rodríguez; Lucía Barbier-Torres; Sara Fernández-Álvarez; Virginia Gutiérrez-de Juan; María J Monte; Emina Halilbasic; Daniel Herranz; Luis Álvarez; Patricia Aspichueta; Jose J G Marín; Michael Trauner; Jose M Mato; Manuel Serrano; Naiara Beraza; María Luz Martínez-Chantar
Journal:  Hepatology       Date:  2014-03-31       Impact factor: 17.425

2.  Identification of a nuclear receptor for bile acids.

Authors:  M Makishima; A Y Okamoto; J J Repa; H Tu; R M Learned; A Luk; M V Hull; K D Lustig; D J Mangelsdorf; B Shan
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

3.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

4.  Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine.

Authors:  Raffaella M Gadaleta; Bas Oldenburg; Ellen C L Willemsen; Maureen Spit; Stefania Murzilli; Lorena Salvatore; Leo W J Klomp; Peter D Siersema; Karel J van Erpecum; Saskia W C van Mil
Journal:  Biochim Biophys Acta       Date:  2011-04-22

5.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

6.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

7.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

8.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

9.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Nuclear receptor small heterodimer partner in apoptosis signaling and liver cancer.

Authors:  Yuxia Zhang; Li Wang
Journal:  Cancers (Basel)       Date:  2011-01-05       Impact factor: 6.639

View more
  26 in total

1.  Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment.

Authors:  Prasant K Jena; Lili Sheng; Hui-Xin Liu; Karen M Kalanetra; Annie Mirsoian; William J Murphy; Samuel W French; Viswanathan V Krishnan; David A Mills; Yu-Jui Yvonne Wan
Journal:  Am J Pathol       Date:  2017-07-12       Impact factor: 4.307

2.  Family reunion of nuclear hormone receptors: structures, diseases, and drug discovery.

Authors:  H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2015-01       Impact factor: 6.150

3.  Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.

Authors:  Lucía Barbier-Torres; Naiara Beraza; Pablo Fernández-Tussy; Fernando Lopitz-Otsoa; David Fernández-Ramos; Imanol Zubiete-Franco; Marta Varela-Rey; Teresa C Delgado; Virginia Gutiérrez; Juan Anguita; Albert Pares; Jesús M Banales; Erica Villa; Juan Caballería; Luis Alvarez; Shelly C Lu; Jose M Mato; María Luz Martínez-Chantar
Journal:  Hepatology       Date:  2015-07-31       Impact factor: 17.425

4.  Pleiotropic roles of FXR in liver and colorectal cancers.

Authors:  Xiongfei Huang; Mingjie Fan; Wendong Huang
Journal:  Mol Cell Endocrinol       Date:  2022-01-04       Impact factor: 4.102

5.  Structural and Functional Analysis of SHP Promoter and Its Transcriptional Response to FXR in Zn-Induced Changes to Lipid Metabolism.

Authors:  Han Gao; Xing Fan; Qi-Chun Wu; Chuan Chen; Fei Xiao; Kun Wu
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

6.  Metabolic characteristics distinguishing intrahepatic cholangiocarcinoma: a negative pilot study of (18)F-fluorocholine PET/CT clarified by transcriptomic analysis.

Authors:  Sandi A Kwee; Gordon S Okimoto; Owen Tm Chan; Maarit Tiirikainen; Linda L Wong
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28

7.  Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation.

Authors:  Lili Sheng; Prasant Kumar Jena; Ying Hu; Hui-Xin Liu; Nidhi Nagar; Karen M Kalanetra; Samuel William French; Samuel Wheeler French; David A Mills; Yu-Jui Yvonne Wan
Journal:  J Pathol       Date:  2017-11-01       Impact factor: 7.996

Review 8.  The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.

Authors:  Lulu Sun; Jie Cai; Frank J Gonzalez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 9.  Non-coding RNA crosstalk with nuclear receptors in liver disease.

Authors:  Jianguo Wu; Laura E Nagy; Suthat Liangpunsakul; Li Wang
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-24       Impact factor: 5.187

Review 10.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.